Gene · 8081
Papers1,614
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,614
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses. | Front Cell Infect Microbiol | 2023 | 37274315 | PubTator, text mining | PubMed |
| Vaccines against Tuberculosis: Where Are We Now? | Vaccines (Basel) | 2023 | 37243117 | PubTator, text mining | PubMed |
| Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 | 37188783 | PubTator, text mining | PubMed |
| T cell immunotherapy for cervical cancer: challenges and opportunities. | Front Immunol | 2023 | 37180106 | PubTator, text mining | PubMed |
| Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer. | Viruses | 2023 | 37112881 | PubTator, text mining | PubMed |
| Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity. | Vaccines (Basel) | 2023 | 37112696 | PubTator, text mining | PubMed |
| High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity. | Nat Immunol | 2023 | 37095378 | PubTator, text mining | PubMed |
| Identification of differentially recognized T cell epitopes in the spectrum of Mtb infection. | bioRxiv | 2023 | 37090558 | PubTator, text mining | PubMed |
| Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models. | Vaccine | 2023 | 37085458 | PubTator, text mining | PubMed |
| HDAd6/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells. | Mol Ther Methods Clin Dev | 2023 | 37081854 | PubTator, text mining | PubMed |
| Trim-Away ubiquitinates and degrades lysine-less and N-terminally acetylated substrates. | Nat Commun | 2023 | 37061529 | PubTator, text mining | PubMed |
| Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment. | Cancers (Basel) | 2023 | 37046608 | PubTator, text mining | PubMed |
| Efficacy and safety of COVID-19 vaccines for patients with spinal tumors receiving denosumab treatment: An initial real-clinical experience study. | Front Oncol | 2023 | 37035168 | PubTator, text mining | PubMed |
| Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials. | J Cancer Res Clin Oncol | 2023 | 37031291 | PubTator, text mining | PubMed |
| Adenovirus core protein V reinforces the capsid and enhances genome release from disrupted particles. | Sci Adv | 2023 | 37027464 | PubTator, text mining | PubMed |
| Molecular and Epigenetic Control of Aldosterone Synthase, CYP11B2 and 11-Hydroxylase, CYP11B1. | Int J Mol Sci | 2023 | 36982850 | PubTator, text mining | PubMed |
| Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. | Front Immunol | 2023 | 36911730 | PubTator, text mining | PubMed |
| Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2. | Front Immunol | 2023 | 36911687 | PubTator, text mining | PubMed |
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. | Lancet Respir Med | 2023 | 36898400 | PubTator, text mining | PubMed |
| Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. | Asian J Pharm Sci | 2023 | 36896445 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8081/papers?page=5